Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 9, 2025

The Board announces that at the EGM held on October 9, 2025, the proposed resolution as set out in the notice of the EGM was duly passed by the shareholders of the Company by way of poll.

The board (the "**Board**") of directors (the "**Directors**") of WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司* (the "**Company**") announces that at the extraordinary general meeting of the Company (the "**EGM**") held on October 9, 2025, the proposed resolution as set out in the notice of the EGM was duly passed by the shareholders of the Company by way of poll. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the circular dated September 22, 2025 (the "**Circular**"). The executive Directors, Dr. Jincai Li and Mr. Jerry Jingwei Zhang; the non-executive Directors, Dr. Zhisheng Chen and Ms. Ming Shi; and the independent non-executive Directors, Mr. Kenneth Walton Hitchner III and Mr. Hao Zhou attended the EGM either in person or by electronic means.

The poll results taken at the EGM were as follows:

ORDINARY RESOLUTION		Number of Votes (Approximate %)	
		For	Against
1.	(i) the subscription agreement dated September 3, 2025 (the "**Subscription Agreement**") (a copy of which is tabled at the EGM and marked "A" and signed by the chairman of the EGM for identification purposes) entered into between the Company (as issuer) and WuXi Biologic (Cayman) Inc. (the "**Subscriber**") (as subscriber), pursuant to which the Company has conditionally agreed to issue and allot to the Subscriber, and the Subscriber has conditionally agreed to subscribe for, 24,134,000 new shares of the Company (each, a "**Subscription Share**") at HK$58.85 per Subscription Share, and all the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;	382,830,040 (100%)	0 (0%)
	(ii) subject to the Listing Committee having granted the listing of, and permission to deal in the Subscription Shares, the Directors be and are hereby granted with a specific mandate (the "**Specific Mandate**") which shall entitle the Directors to exercise all the powers of the Company to issue and allot up to 24,134,000 Subscription Shares to the Subscriber, on and subject to the respective terms and conditions of the Subscription Agreement, provided that the Specific Mandate shall be in addition to, and shall not prejudice or revoke any general or specific mandate(s) which has/have been granted or may be granted from time to time to the Directors prior to the passing of this resolution; and	382,830,030 (100%)	0 (0%)
	(iii) any Director or any other person authorized by the Board be and is hereby authorized to do all such acts and things, sign and execute all such documents or agreements or deeds and take all such actions on behalf of the Company as he/she may in his/her absolute discretion consider necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Subscription Agreement or any transactions contemplated thereunder and all other matters incidental thereto or in connection therewith, and agree to and make such variations, amendments or waivers of any of the matters relating thereto or in connection therewith as are, in his/her opinion, in the interest of the Company and its shareholders as a whole.	382,830,030 (100%)	0 (0%)

As at the date of the EGM, the total number of shares of the Company in issue was 1,228,706,532 Shares. As stated in the Circular, WuXi Biologics (a controlling shareholder of the Company) and Dr. Zhisheng Chen (a director of WuXi Biologics and the Company) and their respective associates holding Shares were required to abstain and they had abstained from voting on the resolution numbered 1 in respect of the Subscription Agreement and the Specific Mandate proposed at the EGM.

To the best knowledge and belief of the Company, after making all reasonable enquiries, as at the date of the EGM, (i) WuXi Biologics and its associates hold 611,350,500 Shares; and (ii) Dr. Zhisheng Chen and his associates hold 418,878 Shares.

Accordingly, as at the date of the EGM, the total number of Shares entitling the holders to attend and vote on resolution numbered 1 were 616,937,154 Shares. The Company did not hold any treasury Shares or repurchased Shares pending cancellation.

Save as disclosed above, there were no restrictions on any shareholders of the Company to cast votes on the resolution proposed at the EGM. No shareholder of the Company has stated his/her/its intention in the Company's Circular to vote against or to abstain from voting on the resolution at the EGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the EGM.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincai LI
Executive Director and Chief Executive Officer

Hong Kong, October 9, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincai LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Ms. Ming SHI and Dr. Jijie GU as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

* *For identification purpose only*